Graft-Versus-Host Disease Prevention by Rapamycin: Cellular Mechanisms

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 5 A, 2000, Pages 529-536

  Chen, Benny J ^a   Morris, Randall E ^a   Chao, Nelson J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Graft versus host disease; Rapamycin; Suppressor cells; Tolerance

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN; RAPAMYCIN;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL TRANSPLANTATION; COCULTURE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FLOW CYTOMETRY; GERMFREE ANIMAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE CULTURE; MOUSE; PATHOLOGY; RADIATION CHIMERA; SKIN; SPLEEN;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR LYMPHOCYTE STIMULATORY ANTIGENS; RADIATION CHIMERA; SIROLIMUS; SKIN; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034571546     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70062-0     Document Type: Article

References (48)

1. Deeg HJ, Klingemann H-G, Phillips GL. A Guide to Bone Marrow Transplantation. Berlin, Germany: Springer-Verlag; 1992.
2. Thomas ED. Pros and cons of stem cell transplantation for autoimmune disease. J Rheumatol. 1997;48(suppl):100-102.
3. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature. 1984;307:168-170.
4. Chao NJ. Graft versus host disease following allogeneic bone marrow transplantation. Curr Opin Immunol. 1992;4:571-576.
5. Chao NJ, Schmidt GM, Niland JG, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329:1225-1230.
6. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JL, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease. New York, NY: Marcel Dekker; 1997:525-559.
7. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic, I: Taxonomy of the producing steptomycete and isolation of the active principle. J Antibiot. 1975;28:721-726.
8. Fabian MA, Denning SM, Bollinger RR. Rapamycin suppression of host-versus-graft and graft-versus-host disease in MHC-mismatched rats [abstract]. Transplant Proc. 1992;24:1174.
9. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993;151:5726-5741.
10. Sharma VK, Li B, Khanna A, Sehajpal PK, Suthanthiran M. Which way for drug-mediated immunosuppression? Curr Opin Immunol. 1994;6:784-790.
11. Metcalfe SM, Richards FM. Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation. 1990;49:798-802.
12. Dumont F, Melino J, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK506 and rapamycin. J Immunol. 1990;144:251-258.
13. Bierer BE, Schreiber SL, Burakoff SJ. The effect of the immuno-suppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol. 1991;21:439-445.
14. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III: In vitro and in vivo evaluation. J Antibiot. 1978;31:539-545.
15. Chen H, Luo H, Daloze P, Xu D, Wu J. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. J Immunol. 1994;156:3107-3118.
16. Schlegel PG, Vaysburd M, Butcher EC, Chao NJ. Inhibition of T cell co-stimulation by VCAM-1 prevents murine graft-versus-host disease. J Immunol. 1995;155:3856-3865.
17. Claman HN, Jaffee BD, Huff JC, Clark RA. Chronic graft-versus-host disease as a model for scleroderma. II: Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985;94:73-84.
18. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med. 1987;165:1552-1564.
19. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol. 1987;139:2511-2515.
20. Piguet PF, Grau GE, Allet B, Vasalli P. Tumor necrosis factor is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med. 1987;166:1280-1289.
21. Bindl JM, Warnke RA. Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in coplin jars. Am J Clin Pathol. 1986;85:490-493.
22. Ando KI, Isobe KI, Hasegawa T, et al. Genetic and stimulator cell requirements for generation and activation of minor histocompatibility antigen-specific memory cytotoxic T-lymphocyte precursors. Immunology. 1988;64:661-667.
23. Morecki S, Leshem B, Weigensberg M, Bar S, Slavin S. Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation. Transplantation. 1985;40:201-210.
24. Hamilton BL, Bevan MJ, Parkman R. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J Immunol. 1981;126:621-625.
25. Jaffee BD, Claman HN. Chronic graft-versus-host (GVHD) as a model for scleroderma. I: Description of model systems. Cell Immunol. 1983;77:1-12.
26. Kappler J, Wade T, White J, et al. A T cell receptor Vβ segment that imparts reactivity to a class-II major histocompatibility complex product. Cell. 1987;49:263-271.
27. + thymocytes. Nature. 1988;333:742-746.
28. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 1990;63:1249-1256.
29. + T cells by staphylococcal enterotoxin B. J Exp Med. 1990;172:1091-1100.
30. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994;6:797-807.
31. Ramsdell F, Lantz T, Fowlkes BJ. A nondeletional mechanism of thymic self tolerance. Science. 1989;246:1038-1041.
32. Morahan G, Allison J, Miller JFAP. Tolerance of class I histocompatibility antigens expressed extrathymically. Nature. 1989;339:622-624.
33. a expressing cells. Nature. 1989;339:541-544.
34. Blackman MA, Finkel TH, Kappler J, Cambier J, Marrack P. Altered antigen receptor signaling in anergic T cells from self-tolerant T-cell receptor β-chain transgenic mice. Proc Natl Acad Sci U S A. 1991;88:6682-6686.
35. Benacerraf B, Germain RN. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. Scand J Immunol. 1981;13:1-10.
36. Sykes M, Sachs DH, Strober S. Mechanism of tolerance. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston, MA: Blackwell Scientific Publications; 1994:204-219.
37. Ricordi C, Tzakis AG, Zeevi A, et al. Reversal of graft-versus-host disease with infusion of autologous bone marrow. Cell Transplant. 1994;3:187-192.
38. Mebta J, Powels R, Singbal S, Horton C, Treleaven J. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant. 1996;17:213-217.
39. Azuma E, Kaplan J. Role of lymphocyte-activated killer cells as mediators of veto and natural suppression. J Immunol. 1988;141:2601-2606.
40. Sykes M, Eisentbal A, Sachs DH. Mechanism of protection from graft-versus-host disease in murine mixed allogeneic chimeras, I: Development of a null cell population suppressive of CML responses and derived from the syngeneic bone marrow component. J Immunol. 1988;140:2903-2911.
41. - αβ bone marrow T cells with suppressor activity. J Immunol. 1992;148:373-380.
42. + cell lines. Cell Immunol. 1990;129:478-493.
43. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
44. - surface phenotype and the α, β heterodimer of the T cell antigen receptor. J Immunol. 1989;143:1118-1122.
45. Strober S, Palathumpat V, Schwadron R, Hertel-Wulff B. Cloned natural suppressor cells prevent lethal graft-vs-host disease. J Immunol. 1987;138:699-703.
46. Hutchinson IV. Suppressor T cells in allogeneic models. Transplantation. 1986;41:547-555.
47. Palacious R, Moller G. T cell growth factor abrogates Con A-induced suppressor cell function. J Exp Med. 1981;153:1360-1365.
48. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest. 99:1118-1129.